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Background: Loxoscelism is the envenomation caused by the bite of Loxosceles spp. spiders. It entails severe
necrotizing skin lesions, sometimes accompanied by systemic reactions and even death. There are no diagnostic
means and treatment is mostly palliative. The main toxin, found in several isoforms in the venom, is
sphingomyelinase D (SMD), a phospholipase that has been used to generate antibodies intended for medical
applications. Nucleic acid aptamers are a promising alternative to antibodies. Aptamers may be isolated from a
combinatorial mixture of oligonucleotides by iterative selection of those that bind to the target. In this work, two
Loxosceles laeta SMD isoforms, Ll1 and Ll2, were produced in bacteria and used as targets with the aim of
identifying RNA aptamers that inhibit sphingomyelinase activity.
Results: Six RNA aptamers capable of eliciting partial but statistically significant inhibitions of the sphingomyelinase
activity of recombinant SMD-Ll1 and SMD-Ll2 were obtained: four aptamers exert ~17% inhibition of SMD-Ll1, while
two aptamers result in ~25% inhibition of SMD-Ll2 and ~18% cross inhibition of SMD-Ll1.
Conclusions: This work is the first attempt to obtain aptamers with therapeutic and diagnostic potential for
loxoscelism and provides an initial platform to undertake the development of novel anti Loxosceles venom agents.
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The envenomation resulting from the bite of spiders of
the genus Loxosceles is called loxoscelism [1-3]. It is
characterized by severe necrotizing wounds in the skin
(cutaneous loxoscelism), which are sometimes accompan-
ied by systemic reactions that can lead to death (viscerocu-
taneous loxoscelism). A distinctive skin ulcer develops
rapidly, within days, but may take months to heal leaving
behind disfiguring scars. In the more severe systemic form
of poisoning, which has a higher incidence in children,
intravascular hemolysis may cause anemia and acute renal
failure within 72 hours. There are no diagnostic means
available and treatment is mainly palliative.
Loxosceles spiders are mostly found in the warm and
tropical climate areas of the Americas. Loxosceles reclusa* Correspondence: asapag@uchile.cl
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unless otherwise stated.(brown recluse spider) and L. deserta account for most
cases of loxoscelism in the United States. In South America,
the three major species responsible for envenomation are
L. intermedia, L. gaucho and L. laeta [2]. The frequency of
viscerocutaneous loxoscelism is higher (~15%) in geo-
graphic areas where L. laeta is the predominant species,
such as Chile [4], Peru, and certain regions of Brazil [5].
The actual incidence of envenomation is not known be-
cause the spider is seldom captured and presented at the
time of medical evaluation.
The venom of Loxosceles spiders contains several toxins
[6], including multiple isoforms of sphingomyelinase D
(SMD) [7], a phospholipase capable of eliciting biological
damage similar to that of whole venom, i.e., dermone-
crosis, platelet aggregation and hemolysis [7-9]. Sphin-
gomyelinase D has two known substrates: sphingomyelins,
which are abundant in cell membranes —especially in
skin and erythrocytes— and give rise to phosphocera-
mides, and lysophosphatidylcholine, a substrate abun-
dant in plasma, which generates lysophosphatidic acid,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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SMDs have been cloned, sequenced and characterized,
such as several from L. laeta [8,11-13], L. intermedia
[14], L. reclusa and L. boneti [15].
Although there are several Loxosceles antivenoms
commercially available [2,16], their safety and efficacy
remain controversial. Given that equine hyperimmune
sera may cause allergic reactions, therapeutic antibodies
obtained against recombinant SMDs [13,17] are under
preclinical development. For example, an antiserum raised
against a toxic recombinant SMD from L. laeta can block
the skin lesion caused by whole L. laeta venom in rabbits
[8]; similar immunoprotection using a nontoxic recombin-
ant SMD has been reported [11]. Monoclonal antibodies
are also capable of neutralizing dermonecrotic and lethal-
ity effects of Loxosceles venoms but do not always confer
cross species protection [18,19]. Antigenic cross reactivity
[e.g., 13,17,20-22] is relevant to the development of wide
spectrum Loxosceles antivenoms. Although significant re-
activity and dermonecrotic protection has been reported
between some species, Olvera et al. [13] suggest that
the sequence divergence of the L. laeta SMDs (e.g., only
40% identity with L. boneti SMD) may account for their
lack of in vitro and in vivo responsiveness to cross species
antisera. Thus, treatment for envenomation by L. laeta
requires special attention.
In spite of their widespread use in therapeutics, anti-











Figure 1 Iterative in vitro selection of RNA aptamers (SELEX).animals for their development, immunogenicity, limited
stability, and elevated costs. Nucleic acid aptamers over-
come these limitations and are thus a promising alter-
native to antibodies. RNA or DNA oligonucleotides that
have been selected for their ability to bind to other mol-
ecules with high affinity and high specificity have great
applicability in therapeutics [23]. In particular, an apta-
mer having the capacity to bind to a Loxosceles sphingo-
myelinase D and abolish its enzymatic activity would
have potential as an antidote for loxoscelism. Aptamers
may be obtained by an iterative in vitro selection strat-
egy (Figure 1) known as “systematic evolution of ligands
by exponential enrichment” (SELEX) (reviewed by Stol-
tenburg et al. [24]). An oligonucleotide library of ≥1013
different sequences, typically ≤100 nucleotides long, is
subjected to in vitro selection based on the desired bio-
logical activity, usually the affinity for a particular tar-
get. The molecules which satisfy the selection criterion
are separated from those that do not and, following an
amplification step, are subjected to a new selection
round; this cycle is usually performed 4–20 times. Amp-
lification is done by the polymerase chain reaction
(PCR) or, in the case of RNA aptamers, by reverse tran-
scription, PCR, and in vitro transcription. Finally, apta-
mers are cloned, sequenced, and tested individually for
binding or other biological activity. In this work, RNA
aptamers selected for binding to L. laeta SMD isoforms












Figure 2 Effect of pools of RNA selected for binding to SMD-Ll1
(SELEX E and SELEX F) or to SMD-Ll2 (SELEX G) on the activity
of their cognate enzyme. Activity of SMD-Ll1 or SMD-Ll2 in the
presence of all pools of RNA obtained from SELEX E (top, Ll1), SELEX
F (middle, Ll1) or SELEX G (bottom, Ll2) at SMD:RNA molar ratios of
1:1 was calculated from fluorescence measurements. SMD activity is
expressed as percent of the fluorescence counts obtained with each
protein in the absence of RNA (black bars). Data shown are averages
of three experiments (n = 3), each in triplicate (SELEX E and F) or
duplicate (SELEX G), ± standard error of the mean (SEM). Significant
differences (P < 0.001), determined by ANOVA of repeated measures
and the Tukey post-test, are shown as §, relative to protein alone in
the absence of RNA; *, relative to s1; and †, relative to s12.
Sapag et al. Biological Research 2014, 47:2 Page 3 of 10
http://www.biolres.com/content/47/1/2were obtained and analyzed for their capacity to inhibit
sphingomyelinase activity.
Results
Selection of aptamers capable of binding to Loxosceles
laeta SMDs
RNAs that bind to either isoform Ll1 or Ll2 of sphingo-
myelinase D were obtained by selection from starting ran-
dom RNA pools having ~1013 different sequences. For
SMD-Ll1, two independent iterative selection (SELEX)
processes, E and F, were performed at protein:RNA ratios
of 1:10 and 1:5 using 10 or 20 pmoles of SMD-Ll1 respect-
ively and 100 pmoles of RNA. Identical initial pools of
RNA (named s0: selected 0 times) were used for E and F.
Twelve selection cycles were carried out for SELEX E and
ten for SELEX F. For SMD-Ll2, an iterative selection of
12 cycles, called SELEX G, was performed at a protein:
RNA ratio of 1:10 using 10 pmoles of SMD-Ll2. The RNA
molecules of the initial pool (s0) were different from those
used for E and F.
Inhibition of sphingomyelinase activity by pools of
selected RNA
The sphingomyelinase activity of recombinant toxins was
measured in the presence of the RNA recovered from
each selection round of SELEX E, F, and G (s1 through
s12) to determine its apparent inhibitory capacity; assays
were done using protein:RNA molar ratios of 1:1. In all
cases (E, F and G) (Figure 2) sphingomyelinase activity in
the presence of RNA from the initial cycles (s1-s3) was
greater than that of protein alone. SELEX E (Ll1) and
SELEX G (Ll2) behaved similarly in that the activity
obtained with s1 RNA dropped gradually along the
first 4–8 cycles followed by an increase in activity in
cycle 9 and thereon (more pronounced and significant in
E). For SMD-Ll1 (SELEX E), activity reaches a 9% max-
imum reduction on s8 (25% reduction between s1 and s8,
P < 0.001). For SMD-Ll2, activity also reaches a maximum
reduction (3.3%) on s8 (17.6% reduction between s1 and
s8, P < 0.001). Accordingly, RNA pools Es8 and Gs8 were
chosen for cloning to isolate and characterize individual
aptamers with therapeutic potential. RNA pools Es12 and
Gs12 were also cloned; their binding affinity is expected to
be greater than that of s8 RNAs and, therefore, they may
have greater potential for diagnostics. SELEX F (Ll1), in
which the selection pressure was less than that applied in
SELEX E, allowed reaching a 25% reduction (P < 0.001) of
SMD-Ll1 activity with s10 RNA (last round performed),
suggesting that even more profound effects might be
attained in additional selection rounds.
Sequence characterization of individual aptamers
The DNA pools encoding RNA molecules from selection
rounds Es8, Es12 and Fs10 (selected for binding toSMD-Ll1), and selection rounds Gs8 and Gs12 (selected
for binding to SMD-Ll2), were cloned in pUC19. Indi-
vidual clones (~50 from each pool) were sequenced, and
reliable sequences (on average 90%) were analyzed to
establish families of related aptamer sequences. Taking
into account the 60 random nucleotides in the center of
each 107 nt aptamer, sequence identity within a family
was > 92% (i.e., less than 5 nt differed between family
members, typically 2 or 3), while identity between
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others in that cohort were termed orphan sequences.
Analysis of cohort Es8 revealed 49/54 clones (91%)
grouped in 6 families, and 5 orphan sequences; of 26
unique sequences the most frequent one was found in 9
clones. Similarly, cohort Es12 had 36/40 clones (90%)
belonging to 7 sequence families, and 4 orphan sequences.
Of 24 unique sequences the most frequent one was found
in 5 clones, and 7 (29%) were also present in cohort Es8.
Cohort Fs10 had 42/47 clones (89%) that could be
grouped in 9 sequence families, and 5 orphan sequences.
Of 32 unique sequences the most frequent one was found
in 6 clones, and 11 (34%) had already been found in
SELEX E: Fs10 shares 7 sequences with both Es8 and
Es12, 2 with Es8 only, and 2 with Es12 only. Thus, inde-
pendent selection processes E and F, both performed with
SMD-Ll1 and starting from the same ~1013 RNA variants,
led to common aptamers.
As for the iterative selection performed by affinity for
SMD-Ll2, analysis of cohort Gs8 revealed 35/49 clones
(71%) grouped in 11 sequence families, and 14 orphan
sequences; of 37 unique sequences the most frequent
one was found in 8 clones. Similarly, cohort Gs12 had
42/52 clones (82%) belonging to 9 sequence families,
and 10 orphan sequences. Of 29 unique sequences the
most frequent one was found in 13 clones, and 8 (28%)
were also present in cohort Gs8.
As expected, no sequences were found to be common
between the SMD-Ll1 and the SMD-Ll2 selections;
SELEX E (and F) and SELEX G were initiated with RNA
pools that were theoretically entirely different given that
they originated from different aliquots of the random
oligonucleotide synthesis. Es8, Fs10 and Gs12 were chosen
for functional characterization of individual aptamers.
Functional characterization of individual aptamers
All unique aptamers (either orphans or belonging to se-
quence families) found in cohorts Es8 and Gs12 were
tested for their capacity to inhibit the enzymatic activity
of their cognate sphingomyelinase; Fs10 aptamers not
found in Es8 were also assayed. The SMD:RNA molar
ratio used in this inhibition assay (Figure 3) was 1:10,
both for individual aptamers as well as for their pools of
origin.
In cohort Es8 (Figure 3, top panel) there were four
aptamers that elicited 16–17% inhibition of SMD-Ll1
(P < 0.001); none of the orphan aptamers elicited a sig-
nificant reduction in sphingomyelinase activity. The se-
quences of these leading aptamers, Es8-6 (family #6),
Es8-7 and Es8-9 (family #2), and Es8-20 (family #1) were
not the most abundant in the group, but three of them
belong to the two most populated families in Es8. Three
of these aptamers arose independently in both SELEX E
and SELEX F, namely, Es8-6, Es8-7, and Es8-20, onefrom each family. These aptamers elicit inhibitions that
are very similar to or greater than the apparent inhibitory
capacity of the Es8 RNA pool or the Fs10 pool (~17% vs.
15% or 3% respectively). None of the aptamers unique to
Fs10 displayed significant reductions of SMD-Ll1 activity
(Figure 3, middle panel).
In cohort Gs12 (Figure 3, bottom panel) there were
two aptamers that elicited ~23% and ~26% inhibition of
SMD-Ll2 (P < 0.05 and P < 0.01); none of the orphan apta-
mers elicited significant reductions in sphingomyelinase
activity (data not shown). Although the two leading apta-
mers —Gs12-62 (family #2) and Gs12-70 (family #3)—
were found in only one copy amongst the 52 clones se-
quenced, they belong to the second and third most
populated families in Gs12, two families which had
already arisen in Gs8. As expected for some individual
aptamers, these leaders elicit inhibitions greater than
that of the Gs12 RNA pool (~25% vs. 12%).
Worth noting is that RNA pools elicit different inhibi-
tions of sphingomyelinase activity depending on the
SMD:RNA ratio used in the assay, 1:1 (Figure 2) or 1:10
(Figure 3). This may be explained by the fact that these
are pools of many RNAs, each having a unique combin-
ation of binding affinity and inhibitory capacity and each
represented in a different number of copies; the possible
RNA-RNA interactions in each pool are likewise unique.
Depending on which set of aptamers coexist in a given
pool, the overall behavior is as likely to change in one dir-
ection or the other when the SMD:RNA ratio is changed.
An interesting question to address is whether the best
two inhibitory aptamers, those selected for binding to
SMD-Ll2, are capable of inhibiting a noncognate SMD.
Cross activity experiments (Figure 4) show that aptamers
Gs12-62 and Gs12-70 clearly exert a significant inhibi-
tory effect on SMD-Ll1 (~18%).
Discussion
The original gene constructs from which SMD-Ll1 and
SMD-Ll2 were produced in E. coli [13], were not avail-
able for this work. Hence, de novo synthesis was adopted
to generate the cDNAs. Once cloned in the expression
plasmid pQE30-Xa, akin to what was reported in the lit-
erature, no bacterial production of the enzymes was ob-
served. However, recloning in a different vector yielded
the recombinant proteins. Specific activities (± SD) were
approximately 17 ± 6 U/mg for SMD-Ll1 and 159 ± 9 U/mg
for SMD-Ll2, somewhat lower than those reported by
Olvera et al. [13] for recombinant SMD-Ll1 (also tagged
in the N terminus), and for SMD-Ll2 tagged in the C
terminus, 56.8 ± 9.9 and 228.2 ± 58.7 U/mg respectively.
Thus, this is the first report of an active recombinant
SMD-Ll2 bearing the histidine tag on the N terminus;
this variant was expected to be active because the crys-
tallographic data available [25] show both protein ends
Figure 3 Effect of individual RNA aptamers from the Es8, Fs10, and Gs12 cohorts on cognate SMD activity. Activity of SMD-Ll1 and
SMD-Ll2 in the presence of RNA aptamers found in cohorts Es8 (top, Ll1), Fs10 (middle, Ll1), and Gs12 (bottom, Ll2) at SMD:RNA molar ratios of
1:10 was calculated from fluorescence measurements. SMD activity is expressed as percent of the fluorescence counts obtained with each protein
in the absence of RNA (black bars). Data shown are averages of three experiments (n = 3), each in triplicate, ± SEM. The inhibitory effects of the
RNA pools of origin are shown in hatched bars. The dots (•) in each bar represent the number of clones that were found to have the same
sequence as that specific clone. Clones belonging to families are shown in white bars and orphan clones are shown in grey. Significant inhibitions
relative to protein alone were determined by an ANOVA of repeated measures and the Tukey post-test (*** P < 0.001, ** P < 0.01, * P < 0.05).
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tags with factor Xa to preclude any interference during
SELEX were not quantitative but optimization efforts
were not pursued because preliminary studies showed
that aptamer pools with inhibitory activity were obtained,
suggesting that the tags did not hinder selection of RNA
aptamers based on their recognition by the SMD portion
of the recombinant proteins.
The sphingomyelinase activity inhibition data for se-
lected RNA pools show that there are statistically signifi-
cant changes in RNA behavior as selection rounds
proceed, suggesting that selection took place along the
process, even though apparent affinity of selected RNA
pools was not measured. When selection pressure was de-
fined by a 1:10 protein:RNA molar ratio, a net inhibition
of SMD activity became apparent with s4 RNA, reached amaximum with s8 RNA, and was lost or remained stag-
nant (E and G respectively) as selection proceeded, that is,
as apparent affinity is expected to increase. A reasonable
explanation for this behavior, as well as for the activating
effect seen with RNA from the initial rounds (s1-s3), is
that both activating and inhibiting aptamers exist in
the selected pools; given that the selection was carried
out by affinity, some activating or noneffector aptamers
may bind more tightly than inhibitory aptamers, eventu-
ally displacing the latter. Hence, maximum affinity pools
are probably not enriched in the best sphingomyelinase in-
hibitors. It follows that if the selection processes had been
monitored by affinity the best inhibitor pools might have
been overlooked. Given that a good inhibitor necessarily
has to bind, this work suggests that a feasible route to
obtain an aptamer with good therapeutic potential is
Figure 4 Cross effects of leader Gs12 aptamers on SMD-Ll1
activity. Activity of SMD-Ll1 in the presence of RNA aptamers
selected for binding to SMD-Ll2 (Gs12-62 and Gs12-70) at SMD:RNA
molar ratios of 1:10 was calculated from fluorescence measurements.
SMD activity is expressed as percent of the fluorescence counts
obtained with SMD-Ll1 in the absence of RNA (black bar). The effects
of control aptamers selected for binding to SMD-Ll1 are also shown:
Es8-20 (inhibitory RNA), and Es8-35 (noninhibitory RNA). Data shown
are averages of six experiments (n = 6) except for Es8-35 (n = 3), each
in triplicate, ± SEM. Significant inhibitions relative to protein alone
were determined for data in n = 6 by an ANOVA of repeated measures
and the Tukey post-test (*** P < 0.001).
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hibitors, and then by optimization of inhibition and/or
binding capacities.
The maximum inhibitory capacity obtained was ~26%
(aptamer Gs12-70), far from the full inhibition that is
naturally desirable in an antidote. Bearing in mind that
selections were done on the basis of binding —not inhibi-
tory capacity— several additional reasons may explain this
outcome. First, as seen from comparing selection pro-
cesses E and F (Figure 2), a less competitive and slower
SELEX may be better; a protein (SMD-Ll1):RNA ratio of
1:5 allowed the Fs10 pool to exert an inhibition of 25%,
greater than the maximum inhibition obtained when the
selection ratio was 1:10 (9% for Es8). Thus, many good
candidates may have been lost in the early stages of the E
process. Second, sequencing a greater number of clones
per cohort, e.g., 100 clones, might have allowed the identi-
fication of stronger inhibitors. Third, although the initial
DNA pool (s0) was subjected to digestion with XbaI to
avoid selecting clones that would be lost in the final
cloning step, this was not done with HindIII, the other
restriction enzyme used for cloning. Thus, good inhibitors
might have been lost upon cloning. These observations
offer guidelines for future efforts to obtain aptamer anti-
dotes for these SMDs. An alternative route to obtaining
aptamers with greater inhibitory capacity is to optimize
the effects of the best available (partially inhibitory) RNAs;
the finding that two aptamers that differ solely in one
nucleotide, e.g., Gs12-37 and Gs12-70, have different in-
hibitory capacities, suggests that mutagenesis of leader
aptamers might be worthwhile. A SELEX approachstarting from a leader RNA subjected to mutagenesis in
its entire sequence or in only one or several nucleotides,
may be considered.
Conclusions
The application of SELEX technology to obtain thera-
peutic or diagnostic agents for biological toxins has been
reviewed recently [26]. It is a very promising approach
given the advantages inherent to the small size and chem-
ical nature of nucleic acid aptamers when compared to
antibodies. Additionally, nucleic acid aptamers may be
coupled to various detection methods and are thus very
versatile as diagnostic agents [27]. In this work, six RNA
aptamers capable of partial inhibition (16-26%) of two
Loxosceles laeta sphingomyelinases, SMD-Ll1 and SMD-
Ll2, were obtained by iterative selection, constituting an
initial platform for the development of novel nucleic acid
drugs that may be both safe and specific for the venom of
the most dangerous species of the Loxosceles spiders. To
our knowledge, this is the first attempt to obtain aptamers
with therapeutic and diagnostic potential for loxoscelism.
Methods
Synthesis of cDNAs and gene constructs encoding
Loxosceles laeta SMD isoforms
Gene expression constructs encoding recombinant L. laeta
SMDs Ll1 and Ll2 were generated. The 858 bp cDNAs
for the mature form of SMD-Ll1 [GenBank:DQ369999]
and SMD-Ll2 [GenBank:DQ37000] [13] were assembled
in vitro by polymerase chain assembly, which employs
long synthetic oligonucleotides as starting material for
extension and amplification reactions [28]; Pfu DNA
polymerase (Fermentas) was used. For each SMD, 22
overlapping oligonucleotides were designed (overlaps of
18 nts): 2 external oligonucleotides (33 nts each) and 20
internal oligonucleotides (59 nts each), all synthesized
by Integrated DNA Technologies (IDT). Cloning schemes
demanded introducing single nucleotide modifications as
well as the addition of AAG CTT ACT G to the 3′ end to
incorporate a HindIII site. Specifically, for SMD-Ll1, a
nonsilent mutation 26A > T (N9I), and four silent muta-
tions (36 T > C, 462 T > C, 618C > T, 837A > T); for SMD-
Ll2, five silent mutations (141 T > C, 300 T > C, 462 T > C,
618C > T, 837A > T). Each cDNA was assembled in two
halves from which full-length sequences (868 bp) were ob-
tained. Amplicons were purified from agarose gels with
the Wizard SV Gel and PCR Clean-up System (Promega).
The sequences required for protein production and purifi-
cation were provided by directional cloning (blunt end/
HindIII) in pQE30-Xa (Qiagen) (StuI, Klenow, HindIII).
The EcoRI-HindIII fragments from these intermediate
constructs contained sequences encoding a ribosome
binding site, an initiation codon, and a recombinant pro-
tein having a His6 tag, the four residues required for
Figure 5 Recombinant SMD preparations: purity and activity.
The sphingomyelinase activity of pure His6 tagged recombinant
toxins SMD-Ll1 and SMD-Ll2 purified from E. coli lysates was
measured with a fluorescent method employing the Amplex Red
reagent in a microplate reader instrument. A. SDS-polyacrylamide
(10%) gel stained with Coomassie blue showing bacterial lysates and
purified fractions of both SMD-Ll1 and SMD-Ll2. B. Activity curves:
the fluorescence of resorufin is shown in arbitrary units (A.U.)
through time. Data shown are for 100 ng SMD-Ll1; 20 ng SMD-Ll2,
and 4 mU of control sphingomyelinase (Bacillus cereus).
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These fragments were transferred to pGEM-3Zf(+)
(Promega) downstream of the T7 RNA polymerase pro-
moter (EcoRI/HindIII) to generate final gene expression
constructs pCC-8 and pCSL-2 encoding SMD-Ll1 and
SMD-Ll2 respectively. Plasmids were purified from E. coli
DH5α cultures (Wizard Plus SV Minipreps DNA Purifica-
tion System, Promega) and constructs were confirmed by
sequencing (CESAT, Universidad de Chile).
Production and purification of recombinant SMD-Ll1 and
SMD-Ll2
Recombinant SMD-Ll1 and SMD-Ll2 were produced in
E. coli Origami B (DE3) (Novagen) transformed with
pCC-8 or pCSL-2 respectively. Luria broth cultures
(50 mL, 100 μg/mL ampicillin) were grown in 250 mL
flasks at 37°C and 250 rpm to an A600 of 0.5-0.7 (4.5-5 h).
Gene expression was induced with 1 mM IPTG and, after
16 h of growth, 35 mL of culture were harvested by centri-
fugation at 4°C. Cells were resuspended in 5 mL of NPI-10
(50 mM NaH2PO4, 300 mM NaCl, 10mM imidazole) and
lysed by ≥ 4 freeze-thaw cycles (−80°C freezer/37°C water
bath, 30 min each). DNaseI was added (10 μg/mL) and
lysates were incubated 30 min in a 37°C water bath,
clarified by centrifugation (12857 × g, 30 min, 4°C) and
filtered through polyethersulfone membranes (Millex GP,
0.22 μm, Millipore).
Recombinant proteins were purified by affinity chro-
matography using 1 mL size Ni-NTA Superflow car-
tridges (Qiagen). After loading, columns were washed
with 10 volumes of NPI-20 (20 mM imidazole) and
bound proteins were eluted with 10 mL of NPI-250
(250 mM imidazole) in 0.5-1 mL fractions. Purifications
were monitored in 0.1% SDS-10% polyacrylamide gels
and pure fractions were dialysed in 3 mL Slide-A-Lyzer
cassettes (10,000 MWCO) (Pierce) against 50 mM Tris–
HCl pH 8 (Figure 5A). The Micro BCA Protein Assay Kit
(Pierce) was used for quantification in flat bottom clear 96
well plates (Costar 3635) using a bovine serum albumin
(BSA) standard curve; absorbance was measured after 2 h
at 37°C in a Victor X3 (Perkin Elmer) plate reader (560 ±
8 nm). Approximate yields were 6 mg for SMD-Ll1 and
0.5 mg for SMD-Ll2. Both 306 aa recombinant proteins,
of 34.2 and 34.8 kDa respectively, have a synthetic 21 aa
peptide (MRGSH6GSGSGSGIEGR) preceding the 285 res-
idues of mature toxin sequence.
Sphingomyelinase activity measurements
Activity of recombinant proteins was measured in 100 mM
Tris–HCl pH 7.4, 10 mM MgCl2 with the Amplex Red
Sphingomyelinase Assay Kit (Invitrogen) in 200 μL re-
actions (100 μL of sample plus 100 μL working solu-
tion). Fluorescence of resorufin was read in white flat
bottom 96 well plates (Nunc 236108) in a Victor X3instrument for 60–90 minutes (excitation: 544 ± 15 nm,
emission: 590 ± 20 nm). A linear behavior between ac-
tivity and fluorescence was generally obtained through-
out the first 20 minutes (Figure 5B) with 100 and 20 ng
of SMD-Ll1 and SMD-Ll2 respectively; activities were
calculated at 10, 15 or 20 minutes.
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Suitable templates for in vitro transcription were gener-
ated as follows (Figure 6). A long DNA oligonucleotide
(TG-503, 96-mer) having a 60 nt center of random se-
quence flanked by segments A and B was synthesized
(GAA GTT TGA TCA TGG CTC N(60) GGA TAT CTG
AGT CGA GAT). A full-length degenerate duplex (133 bp)
was obtained by PCR amplification of 10 pmoles of
TG-503 (5 U Biolase Taq DNA polymerase (Bioline),
200 μM each dNTP, 10% dimethylsulfoxide, 1.5 mM
MgCl2; 2 min 94°C/30 cycles of 30 sec 94°C, 30 sec
65°C, 2 min 72°C/10 min 72°C) using primers TG-504
and TG-505 (100 pmoles each) in ten 50 μL reactions.
Oligonucleotides TG-503, 504 and 505 (IDT) were de-
signed according to Sapag and Draper [29] with modifica-
tions. Primer TG-504 (CAG TAA GCT TAA TAC GAC
TCA CTA TAG GGA AGT TTG ATC ATG GCT C,
46-mer) anneals to flanking sequence A, provides the
T7 phage RNA polymerase promoter and a HindIII rec-
ognition sequence, while primer TG-505 (CAG TTC
TAG ATC TCG ACT CAG ATA TCC, 27-mer) anneals
to flanking sequence B and carries an XbaI recognition
sequence. The degenerate amplicon was digested with
XbaI and purified from a 3% Nusieve agarose gel.A
B
Figure 6 Synthesis of random sequence template DNA (s0) by PCR. A
TG-504 (46 nt) and TG-505 (27 nt); the template has a 60 nt central region
for T7 RNA polymerase, which allows the generation of RNA by in vitro tran
which allow cloning for the analysis of individual sequences. B. NucleotideTranscription was done at 37°C in 50 μL reactions for
2 hours using ~250 ng of degenerate duplex, 20 U T7
RNA polymerase (Fermentas), and 2 mM each NTP.
Products were precipitated and separated by electrophor-
esis in 8% denaturing (50% urea w/v) polyacrylamide gels
run at 17 W for 1 h. Full-length RNAs were visualized by
UV-shadowing, bands were excised and soaked in water
overnight at 37°C, and RNAs (102 nt) were concentrated
with Amicon Ultra (2 mL 30 K) centrifugal filters. RNA
concentrations were measured by absorbance at 260 nm.
Selection cycles
Protein and RNA were prepared separately for binding in
equal volumes (25 μL) prior to mixing (50 μL). Typically,
10 pmoles of toxin (~0.3 μg) and 100 pmoles of RNA
(~3.3 μg) were used (1:10 molar ratio). The protein was in-
cubated in 100 mM Tris–HCl pH 7.4 for 20 min at 37°C
and 10 min at room temperature. The RNA was renatured
in 100 mM Tris–HCl pH 7.4 and 20 mM MgCl2 for
20 min at 42°C and 10 min at room temperature. After
combining the two, binding conditions being 100 mM
Tris–HCl pH 7.4 and 10 mM MgCl2, mixtures were incu-
bated for 10 minutes at room temperature. Filtration
through nitrocellulose membranes (Whatman # 7182–002,. Amplification of oligonucleotide TG-503 (96 nt) by PCR with primers
of random sequence. The resulting s0 DNA (133 bp) has a promoter
scription, and recognition sites for restriction enzymes HindIII and XbaI,
sequence of s0 DNA.
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bound to the protein (retained on the filter) from those that
were unable to bind. Filters were washed twice with 200 μL
of binding buffer. The bound (selected) RNAs were recov-
ered from the filter (cut into 2×2 mm pieces) by soaking
for 1 h at room temperature in 200 μL of 10 mM Tris–HCl
pH 7.4 and 400 μL of water saturated phenol; RNAs were
precipitated using 20 μg of glycogen (Roche) as carrier and
resuspended in water.
RNAs selected in each cycle were reverse transcribed
in one 20 μL reaction. Briefly, the RNA was incubated in
standard buffer with 0.5 mM each dNTP and 100 pmoles
TG-505 for 10 min at 55°C and switched to ice prior to
the addition of 200 U of M-MLV reverse transcriptase
(Promega) and incubation at 42°C for 1 h. Following pre-
cipitation, the entire cDNA preparation was amplified in
5 PCR reactions with primers TG-504 and TG-505. The
DNA was pooled, precipitated, and full-length mole-
cules were purified from a 3% Nusieve agarose gel.
Enough RNA for the next selection step was generated
from this DNA (which was not subjected to XbaI diges-
tion) in 5 in vitro transcription reactions, each with
250 ng of template. Reactions were pooled, nucleic acids
were precipitated, and the full-length RNA (107 nt) was
purified from polyacrylamide gels, concentrated, and
used for the next selection cycle.
Inhibition of sphingomyelinase activity by pools of
selected RNA
Binding reactions were performed as indicated for the
selection steps but at protein:RNA molar ratios of 1:1,
using 100 ng of SMD-Ll1 and 20 ng of SMD-Ll2 per en-
zymatic assay. Enough protein for a group of assays was
prepared for binding in one tube (25 μL per assay) while
RNAs from different selected pools were renatured indi-
vidually in one tube per assay (25 μL). The protein was
added to the RNA and, after the 10 min binding step,
the protein-RNA mixture was added to 50 μL of binding
buffer in each well of a 96-well plate, making 100 μL of
sample over which 100 μL of Amplex Red working solu-
tion were added to initiate the enzymatic reaction. Sphin-
gomyelinase activity was measured as indicated. Typically,
3 experiments (n = 3) were performed in triplicate. For
each experiment, the average of blank fluorescent counts
was subtracted from individual measurements; triplicates
were averaged and expressed as percent of the activity ob-
tained for the protein in the absence of RNA (100% activ-
ity) in that same experiment. Data were subjected to
analyses of variance (ANOVA) of repeated measures and
the Tukey post-test (GraphPad Prism software).
Cloning of RNA pools and sequencing of individual clones
The cDNAs of some RNA pools were cloned in pUC19
(New England Biolabs) using HindIII and XbaI (fulltranscription units). Clones were sequenced with M13
universal primers in microplate format (Macrogen, USA).
Sequence relatedness between clones was analyzed with
Clustal W 2.1 [30]. Families of sequences (groups compris-
ing two or more clones) were named with increasing num-
bers (starting with family #1 in each cohort) according to
the following hierarchy: total number of clones, number of
identical clones, lowest clone number (clone name).
Inhibition of sphingomyelinase activity by individual RNA
aptamers
Performed as detailed for pools of selected RNA but at
protein:RNA molar ratios of 1:10. Each RNA was gener-
ated in several 50 μL in vitro transcription reactions using
250 ng of template. Duplex templates were obtained by
PCR performed on each plasmid clone with primers TG-
504 or M13-reverse and TG-505 using 1 mM MgCl2
(2 min 94°C/35 cycles of 1 min 94°C, 2 min 60°C, 2 min
72°C/10 min 72°C). Amplicons were precipitated prior to
use as templates. Typical yields were 1 μg of DNA per re-
action and 2–8 μg RNA per transcription. Full length
RNAs were purified as indicated. Large amounts of RNA
were alternatively obtained with the TranscriptAid T7
High Yield Transcription Kit (Thermo Scientific). Typic-
ally, a single 20 μL reaction was carried out for 18 hours
at 37°C using 250 ng of PCR product as template; yields
were 20–80 μg of RNA. Following purification, RNAs
were concentrated by precipitation.
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